We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA REOPENS COMMENT PERIOD ON MANUFACTURING CHANGES
FDA REOPENS COMMENT PERIOD ON MANUFACTURING CHANGES
March 19, 2004
Saying the industry has failed to give it sufficient input, the FDA last week reopened the comment period for a notice on time estimates for collecting information for reporting manufacturing changes on approved new drug applications (NDAs) and abbreviated new drug applications (ANDAs).